Hidden overlap between heart failure with preserved ejection fraction and transthyretin amyloid cardiomyopathy: Why it matters and how to avoid missing it - PubMed
5 days ago
- #Heart Failure
- #Diagnosis
- #Amyloidosis
- Transthyretin cardiac amyloidosis (ATTR-CM) is a treatable cause of heart failure.
- Heart failure with preserved ejection fraction (HFpEF) is a common and heterogeneous syndrome.
- Many HFpEF patients may have undiagnosed ATTR-CM, affecting treatment effectiveness.
- Key diagnostic clues include discordant ECG voltages, pseudo infarct patterns, and apical sparing on strain imaging.
- Bone scintigraphy enables noninvasive ATTR-CM confirmation without monoclonal protein.
- Disease-modifying agents like tafamidis and vutrisiran make early recognition crucial.
- A red-flag based screening framework can reduce missed diagnoses and improve therapy initiation.